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Adverse effects, health service engagement and service satisfaction among anabolic 
androgenic steroid users 
Abstract 
There are a number of adverse health effects associated with the use of anabolic androgenic 
steroids (AAS) ranging from mood disturbances to gynaecomastia and impaired sexual 
function. Despite the potentially serious nature of adverse effects, evidence suggests that 
users are reluctant to seek medical assistance. This study explores factors associated with 
health service engagement and treatments related to service satisfaction among a sample of 
AAS users. The analyses are based on a sample of 195 respondents from the Global Drug 
Survey (GDS) 2015 who reported using steroids in the previous 12 month period and 
experiencing concerns about adverse health effects. The results indicate reluctance among 
AAS users to engage with health services with only 35.23% reporting that they visited a 
doctor when experiencing concerns about adverse effects. Concern about sexual function 
increased the likelihood that users engaged with health services while concern about changes 
in sexual organs decreased the odds of service engagement. Amongst AAS users who 
engaged with health services, individuals who received a mental health assessment or 
diabetes test rated the service as more helpful than those who did not; a finding that resonates 
with literature indicating a desire amongst AAS users to monitor the health impacts of their 
drug use and respond to issues as they arise. While more research is needed, the present 
results underscore a need for non-judgemental health services aimed at assisting AAS users 
to monitor adverse effects and minimize harm through early intervention.  
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Adverse effects, health service engagement and service satisfaction among anabolic 
androgenic steroid users 
Introduction 
The use of anabolic androgenic steroids (AAS) and associated performance and image 
enhancing drugs (PIEDs) is not new. In the past decade, efforts have been made to eliminate 
the use of PIEDs by professional sportspersons and elite athletes. Yet, there is some evidence 
of a concomitant increase during this time in AAS and PIEDs use in the general population 
(Iversen et al., 2013; McCabe et al., 2007; McVeigh & Begley, 2016; McVeigh, Beynon & 
Bellis, 2003). Estimated lifetime prevalence rates, based on population surveys in Australia 
(Dunn, 2010), Norway (Sagoe et al., 2015) and the USA (Pope et al., 2014), range from less 
than 1% to 6% depending on sample characteristics. A recent meta-analysis of 187 studies 
reports a global lifetime prevalence rate of 3.3% (Sagoe et al., 2014).  
Whilst the prevalence of AAS use in the general population appears to be relatively low, the 
perception that use is increasing, particularly among young, recreational gym goers and non-
athletes, is ubiquitous (Bojsen‐Møller & Christiansen, 2010; Chandler & McVeigh, 2013; 
Kanayama & Pope, 2012b; Evans-Brown & McVeigh, 2009; Kimergård &McVeigh, 2014a; 
Sagoe et al., 2014). Recreationally, AAS are used to increase muscle mass, improve physical 
appearance and enhance strength or athletic performance (Brennan et al., 2016; Ip et al., 
2011; Ip et al., 2015). Reasons for initiating use include body dissatisfaction (Kimergård, 
2015); low confidence or poor self-esteem (Cohen et al 2007; Maycock & Howat, 2009); 
safety and security (Maycock & Howat, 2009); to improve social status  (Griffiths et al., 
2015; Maycock & Howat, 2009; Seear et al, 2015) or to fit in to a ‘fitness’ lifestyle or identity 
(Ravn & Coffey, 2016). 
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Whilst health and fitness pursuits are often cited as the main reasons for using AAS (Brennan 
et al., 2016; Ip et al., 2011; 2015), research has shown that the use of AAS is associated with 
a number of adverse health effects (Kanayama & Pope, 2012a). Some of these effects are 
acute in nature and naturally subside with cessation of AAS use while others are chronic 
health conditions that develop from long term AAS use (Pope & Kanayama, 2015; Pope et 
al., 2013). Physical side effects include cardiovascular damage, liver disorders (especially if 
administered orally), testicular atrophy, gynaecomastia and loss of sexual function (Pope et 
al., 2013). An association between AAS use and poorer mental health outcomes has also been 
reported (Lindqvust et al., 2013). Adverse effects are not only the purview of long term AAS 
use. Acute effects of AAS use are well described in the literature particularly in relation to 
‘stacking’ (Sagoe et al., 2015), unsafe injecting practices (Dunn et al., 2014; Iversen et al., 
2016) and/or the use of illicitly manufactured products (Evens-Brown et al., 2009).  Research 
has also demonstrated a link between AAS use and negative psychological states including 
anger, depression and anxiety (Pope et al., 2005).  
Despite the potentially serious nature of adverse effects, evidence suggests that AAS users 
are reluctant to seek medical assistance or to reveal their AAS use to their doctor (Pope et al., 
2004). A recent purposive survey of 94 steroid and image enhancing drug (SIED) users in the 
UK found that only 6% reported seeking medical assistance when they experienced adverse 
effects related to AAS use. Users cited lack of understanding from their doctor as one of the 
reasons they did not engage with health services (Chandler & McVeigh, 2013). Similarly, a 
recent convenience study of injecting AAS users revealed only a minority (17%) of AAS 
injectors who experienced redness, swelling or tenderness around the injection site had ever 
sought treatment (Hope et al., 2015). While these studies, based on samples of bodybuilders 
(Chandler & McVeigh, 2013) and needle exchange attendees (Hope et al., 2015), provide 
some insight into the health service experiences of AAS users, this type of detailed 
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information on health service engagement and satisfaction is not currently available from 
general population drug surveys. 
In order to develop appropriate health service responses to AAS use, additional information 
on health service engagement, treatment and satisfaction is required from AAS users in the 
general population. The Global Drug Survey (GDS) is an online, anonymous survey designed 
to capture in-depth information about the use of alcohol, tobacco and illicit substances. The 
GDS includes a range of questions about the use of AAS including items relating to adverse 
effects, health service engagement and service satisfaction. Using a sample of respondents 
from the GDS 2015 who reported using steroids in the previous 12 month period, the current 
study identifies factors associated with health service engagement and examines treatments 
associated with health service satisfaction. Given the growing number and diversity of AAS 
users (Pope & Kanayama, 2015; Rowe et al., 2016; Seer et al., 2015), minimising harm 
associated with AAS use is an important public health concern. The aim of the current 
research is to better understand reasons for health service engagement among AAS users. 
This knowledge is vital to inform the development of health services that are aligned with the 
needs of AAS users, encourage health service engagement among this group and, in turn, 
minimise drug related harms. 
Methods 
Design 
The Global Drug Survey (GDS) is an annual, international, online survey of drug use which 
is self-completed, largely by younger individuals, on a self-nominating, anonymous basis. 
The most recent survey (GDS, 2015) collected data between November 2014 and January 
2015. A total of 89 509 responses were completed during this time. The survey was promoted 
in partnership with a range of media including national newspapers, magazines, web sites and 
social media outlets (GDS, 2015) and was available in 11 languages (English, German, 
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Greek, Polish, French, Italian, Spanish, Portuguese, Flemish, Hungarian and Danish). The 
GDS sample is opportunistic and not intended to be representative of any particular 
population group. Other publications provide details on the design, utility and limitations of 
the GDS (Barratt et al., 2014; GDS, 2015; Winstock et al., 2015).   
GDS respondents were asked whether they had used injectable anabolic steroids or oral 
anabolic steroids in their lifetime and in the last 12 months. The total number of GDS 
participants who reported lifetime steroid use was 1000. This was 1.1% of the total survey 
sample. In the current study the analytic sample is restricted to those who: 1) indicated that 
they used anabolic androgenic steroids (AAS) during the 12 months prior the survey and, 2) 
experienced concerns about adverse effects related to AAS use (n=195).  
Analyses and Measures 
The analyses proceed in three stages. All measures are drawn from the GDS 2015. Stage 1 is 
a logistic regression analysis examining factors associated with health service engagement. 
The dependent variable is a dichotomous indicator drawn from an item in the GDS that asked 
respondents who reported using AAS in the last 12 months whether or not they had discussed 
health concerns related to their AAS use with their family doctor (yes/no). The key 
independent variables are 5 dichotomous indicators capturing concerns about: mood/mental 
health; image; sexual function; sexual organs; organ health.  The 5 variables were constructed 
from 17 items on the GDS that asked individuals who reported using AAS in the last 12 
months to report on a scale of 1 (not at all worried) to 3 (worried a lot) how worried they 
were about seven mental health and ten physical health issues associated with AAS use. For 
each of the 5 variables, respondents were given a score of 1 if they reported concern about the 
health issue and a score of 0 if they reported no concerns about the health issue. The 
construction of the 5 measures was based on existing literature that discusses the adverse 
effects of AAS use as comprising both physical and mental health components (Kanayama & 
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Pope, 2012a; Linqvist et al., 2013; Onakomaiya & Henderson, 2016; Quaglio et al., 2009). 
Physical health concerns were further delineated into those associated with sexual organs; 
sexual function and organ health as responses may be expected to vary by sex and method of 
administration respectively. Item groupings were confirmed using multiple components 
analysis (see Figure 1) and are reported in Table 1. Control variables including age; sex 
(1=female; 2=male); region of residence (1= Europe; 2=North America; 3=South America; 
4=Australia/NZ; 5= Asia/Africa and Middle East); ethnicity (0= Caucasian; 1= other); poly-
PIEDs use (0=no AAS only; 1= yes AAS plus at least 1 other PIED); and method of AAS 
administration (0=oral; 1= inject only; 2= both oral and inject), were also included in the 
logistic regression models.  
Stage 2 of the analyses establishes the proportion of recent AAS users who engaged with 
health services about their AAS use and examines the bivariate relationships between 
treatments received and satisfaction with health services, measured using two items from the 
GDS.  Individuals who reported using AAS in the last 12 months and indicated they had 
engaged with health services in the relation to their AAS use (n=68) were asked to rate their 
experience of raising their steroid use with their doctor on a scale of 1 (very poor) to 5 (very 
good). They were also asked to report on a scale of 1 (not helpful) to 4 (very helpful) how 
helpful their doctor was in addressing health concerns related to their AAS use. Aspects of 
treatment were assessed using eight individual items. Respondents were asked to indicate if 
the following investigations/ conversations were carried out by their doctor (yes/no): physical 
examination; blood pressure; assessment of my mood; blood tests to assess my liver function; 
diabetes test; ECG; screening for hepatitis B / C, HIV; discussion about safer injecting. The 
Wilcoxon-Mann-Whitney test1 was used to assess statistically significant associations 
                                                          
1 The Wilcoxon-Mann-Whitney test is a non-parametric analog to the independent samples t-test and does not 
require that the dependent variable is normally distributed.  
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between treatments received and each of the variables capturing satisfaction with health 
services.  A two-sided p value of <0.05 was considered statistically significant.  
Stage 3 of the analyses describes frequently reported reasons for not engaging with health 
services despite experiencing concerns about AAS related health issues. Those respondents 
who indicated that they did not visit their family doctor about health concerns related to their 
AAS use were asked whether this was for any of the following reasons (yes/no): 
shame/stigma; did not think the doctor would be able/knowledgeable enough to help; did not 
think the doctor would be willing to help; the concerns were not significant enough; worries 
over the impact on health insurance. All analyses were conducted using STATA 13.0. The 
results of each stage of the analyses are reported below. 
>>>Figure 1 here <<< 
 Results 
 The total number of GDS respondents who reported using AAS in the 12 month period 
preceding the survey was 318. This sample of recent AAS users comprised 253 (79.56%) 
men and 59 (18.55%) women with a mean age of 29.8 years (SD=12.35).2 Of those who 
reported using AAS during the last 12 months, 117 (36%) did not record any responses to 
questions asking about adverse effects. The 117 respondents who did not report any concerns 
about adverse effects were eliminated from the analyses leaving an analytic sample of 195. 
Chi-square analyses and independent samples t-tests were conducted to compare the 
demographic characteristics of the 117 participants who did not record any responses to 
questions about adverse effects to the analytic sample. There were no significant differences 
between the two groups of respondents in relation to age, employment status, ethnicity or 
                                                          
2 Transgender individuals were dropped from the sample due to low numbers (n=6). 
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highest level of education. Females were more likely to be non-responders than males, 
𝑥𝑥2(1,𝑁𝑁 = 201) = 49.92 p<0.001). Prior research associates women’s reluctance to divulge 
steroid use with their engagement in drug-tested body building competitions and stigma 
(Korika et al., 1996).  Descriptive statistics are displayed in Table 1.  
>>>Table 1 here<<< 
 
Stage 1: Factors associated with health service engagement  
Sixty-eight (35.23%) respondents reported visiting a doctor within the last year in relation to 
their AAS use. This sub-sample comprised 9 (13.24%) women and 59 (86.76%) men with an 
average age of 35.94 years (SD=13.33). Bivariate statistics revealed that women who 
experienced concerns about adverse effects were more likely to engage with health services 
than men 𝑥𝑥2(1,𝑁𝑁 = 195) = 5.13 p<0.05). On average, AAS users who engaged with health 
services were significantly older than those who did not (t=-5.03, p<0.001).  
Logistic regression models revealed that AAS users who were concerned about the effects of 
their drug use on sexual function were more likely to visit a doctor in relation to their AAS 
use than those who did not experience worry about sexual function (OR=4.02, p<0.01). 
Alternately, individuals who experienced concern about the impact of their AAS use on 
sexual organs were less likely to visit a doctor than individuals who did not experience this 
concern (OR =0.30, p<0.05). Males were less likely to report visiting a doctor about their 
AAS use than females (OR= 0.09, p<0.01). Because it is well known that oral steroid use is 
associated with liver problems but injecting use is not, an interaction between method of 
administration and concern about organ health was included in the model. The interaction 
was moderately significant and indicated that for injecting AAS users, worry about organ 
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health was associated with greater likelihood of visiting a doctor while the opposite was true 
for non-injectors.3 Logistic regression results are reported in Table 2.  
>>>Table 2 here<<< 
 
Stage 2: Health service satisfaction among AAS users who visited a doctor 
Ratings of health service helpfulness and overall experience did not differ by sex (p=1.00; 
p=0.75, FET) and were not significantly associated with age (b=0.03, p=0.18; b=0.25, 
p=0.15)4. Of the 68 AAS users who visited a doctor within the last year, 54 (79.41%) 
reported receiving a physical examination and 55 (80.88%) reported receiving blood tests to 
assess liver function. These were the most frequently reported treatments received. 
Alternately, only 23 (33.82%) respondents reported having a discussion with the doctor about 
their mood and 26 (38.42%) reported receiving an ECG to assess cardiac health (Table 3).  
Individuals who reported discussing their mood with the doctor (z= -2.71, p<0.01) and those 
who were tested for diabetes (z=-2.10, p<0.05) were more likely than those who did not 
receive these treatments to rate the health service as helpful or very helpful. Individuals who 
were screened for hepatitis B/C and HIV were more likely than those who did not receive this 
treatment to rate their overall experience with the doctor as good or very good (z=-2.62, 
p<0.01). Other treatments including, physical examination, blood pressure check, ECG, safe 
injecting education and blood tests for liver function, were not significantly associated with 
health service satisfaction. 
>>>Table 3 here<<< 
                                                          
3 We also tested for interaction effects between method of administration (0=oral 1= inject only 2= oral and 
inject) and all other adverse health effects but none of the other interactions were significant. 
 
4 Sex differences were assessed using Fischer’s exact test. The association between age and indicators of 
satisfaction were assessed using ordinal logistic regression. 
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Stage 3: Reasons for not engaging with health services  
One hundred and thirty (67.36%) respondents did not visit a doctor despite being worried 
about adverse effects related to their AAS use. The most frequently cited reason for not 
engaging with health services was that the condition was not significant enough (n=70, 
53.85%). Approximately one quarter of respondents reported that they did not engage with 
health services because they were not confident that their doctor had the knowledge to help 
(n=31, 23.85%) or they were concerned about stigma/ shame associated with AAS use (n=29, 
22.31%). Eighteen respondents did not think their doctor would be willing to help them with 
an issue related to their AAS use (13.85%). Only three respondents cited concern about 
health insurance as a factor in their decision not to engage with health services in relation to 
their AAS use (2.31%) (Table 4). 
>>>Table 4 here<<< 
Discussion 
In the current study we explored health concerns associated with visiting a doctor among a 
sample of recent AAS users and, among those who did not visit a doctor despite their health 
concerns, we looked at reasons given for not engaging with health services. Our findings 
show that only a minority of AAS users engage with health services when they experience 
health-related concerns about their AAS use, but receiving care specific to conditions 
associated with AAS use, as opposed to more generic treatments facilitated greater health 
service satisfaction. Overall, our findings suggest that to encourage help-seeking among AAS 
users, health service providers must demonstrate that they are both non-judgmental and 
knowledgeable about the use of AAS. These findings offer important insights in the context 
of AAS use being associated with a range of both chronic and acute physical and mental 
health issues (Kanayama & Pope, 2012; Lindqvist et al., 2013; McVeigh & Begley, 2016). 
The incidence and severity of these AAS-related harms may be ameliorated if users engage 
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with health services when concerns first arise. Yet, research suggests that AAS users are 
reluctant to engage with health services and little is known about the types of treatments that 
would encourage help-seeking among this group (Dunn et al., 2016; Kimergård & McVeigh, 
2014b; Pope & Kanayama, 2015). Our study begins to address this knowledge gap. 
The results reveal three key findings. First, in line with previous research we find that a 
minority of AAS users (36.23%) engage with health services when they experience concerns 
related to their AAS use. Commonly reported reasons for not engaging with health services 
reflected those documented in previous studies: the problem was not significant enough; lack 
of confidence in doctors’ knowledge of AAS and concerns about stigma associated with AAS 
use (Chandler & McVeigh, 2013; Hope et al., 2015; Pope et al., 2004; Yu et al., 2015).  
Second, we found that two treatments, mood assessments and diabetes tests, were associated 
with higher ratings of service helpfulness and one treatment, screening for hepatitis B/C, HIV 
was associated with higher ratings of overall experience with the doctor. Treatments that 
aimed to assess health issues related to specific AAS side effects (i.e. diabetes test for insulin 
resistance, hepatitis B/C, HIV screening, mood assessment), as opposed to more generic 
treatments (i.e. physical examination, general blood test) were associated with greater service 
satisfaction. When AAS users receive treatments that can be associated with specific, well-
documented side effects of AAS use, such as insulin resistance, depression (particularly 
during off-cycle) or blood-borne diseases, this may indicate to the user that the doctor is 
knowledgeable, non-judgemental and willing to monitor and manage their AAS-related 
health issues.  Alternately, when AAS users receive more generic treatments, such as a 
physical examination or general blood test, they may perceive that the doctor has limited 
knowledge of health issues specific to AAS use and find the health service less helpful for 
their needs. 
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Additionally, screening for specific health conditions may be perceived as helpful because it 
allows AAS users to continue using the drugs while monitoring the impact on their health and 
countering adverse effects with medical interventions. For example, a diabetes test may lead 
to treatment to counter insulin resistance and prevent hyperglycaemia allowing the user to 
continue taking AAS while managing the adverse effects. Other studies have indicated AAS 
users’ desire to take an active role in monitoring their health (Dunn et al., 2016) and highlight 
the importance of health service providers to be equipped with knowledge specific to the 
effects of AAS use (Holland-Hall, 2007; McVeigh & Begley, 2016). In interviews with AAS 
clinic attendees, Kimergård and McVeigh (2014b) found that AAS users appreciated regular 
medical testing to identify health issues associated with their AAS use as it enabled them to 
take action to counter adverse effects as they arose. This study also reported that steroid 
clinics were popular among users because service providers were non-judgemental and 
knowledgeable about AAS.  
The third key finding is that AAS users who were concerned about the impact of their drug 
use on sexual function were more likely to visit a doctor while those who were concerned 
about the effects of AAS on their sexual organs (size increase/decrease) were less likely to 
engage with health services. A possible explanation for this finding is that AAS users engage 
with health care providers when they perceive the condition to be treatable. The second most 
frequently cited reason for not visiting a doctor to discuss concerns about AAS related health 
issues was a perception that a doctor would not be able to help. While it is commonly known 
that doctors can provide treatment for impotence in the form of prescription medication, users 
may perceive that doctors cannot do anything to treat changes in sexual organs and this may 
deter them from engaging with health services.  The results also revealed that female users 
were more likely than males to visit a doctor to discuss health concerns related to their AAS 
use. This finding was not surprising given that AAS increase circulating levels of the male 
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reproductive hormone, testosterone, the potential for adverse health effects to arise from AAS 
use is greater for women than men (Rasmussen, et al., 2016). Greater potential for adverse 
effects may explain higher levels of engagement with health services among women. 
There is limited research on interventions and harm reduction policies for AAS, especially on 
perceptions of treatment from the users’ perspective. Existing studies that examine AAS 
users’ engagement with traditional drug services (i.e. NSPs) suggest that AAS users are 
reluctant to attend these services for fear of being labelled as a ‘drug user’ (Brennan et al., 
2016; Kimergård & McVeigh, 2014b). Further, NSP workers may be ill-equipped to provide 
advice on intramuscular injecting and AAS dosing given that they may be less familiar with 
steroids than other illicit substances (Dunn et al., 2014; Seer et al., 2015). Given the 
reluctance of AAS users to engage with traditional drug services (Brennan et al., 2016; 
Kimergård & McVeigh, 2014b), family doctors and general practitioners may be an 
important avenue for help-seeking among this group. Our findings suggest that doctors can 
better address the needs of AAS users by assisting them to monitor the impact of their drug 
use on their physical and mental health through regular screening for known side effects of 
AAS and countering health issues as they arise.  
Our findings support the views of previous scholars who have called for better training and 
education for doctors so they can provide credible information to AAS users (Chandler & 
McVeigh, 2013; Pope et al., 2004). Two of the main reasons for not engaging with health 
services were lack of confidence in doctors’ knowledge of AAS and stigma. To be perceived 
as a credible source of health advice, health service providers must acknowledge the benefits 
of AAS (Holland-Hall, 2007). While acknowledging the benefits of AAS use, providers 
should also offer advice on alternative avenues to achieving body and strength goals. Referral 
to a nutritionist, strength coach or mental health service may be appropriate (Holland-Hall, 
2007). Education and training facilitated by current and/or previous AAS users may help to 
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challenge stereotypes of AAS users among health care providers and create an opportunity 
for service providers to learn about the experience of AAS use first-hand. Education should 
also focus on helping health service providers to find subtle ways to demonstrate a non-
judgemental attitude and encourage open conversation about drug use with their patients. 
This may be achieved by engaging in open discussions about health, mood and wellbeing 
with patients presenting for non-drug related health issues who may be at high-risk of AAS 
use, for example, individuals presenting with sports/activity related injuries; individuals from 
high-risk industries (e.g. police, security) presenting for work-related physicals; young men 
reporting sexual dysfunction and/or body dissatisfaction. These types of discussions may also 
help to identify reasons for AAS use such as body dissatisfaction, insecurities, bullying 
and/or pressure to perform (Hanley Santos & Coomber, 2016; Holland-Hall, 2007 ; Ip et al., 
2015; Kanayama et al., 2012; Kimergård, 2015; Maycock & Howat, 2009).  
Limitations 
This study has a number of strengths and limitations worth noting. The GDS is an established 
survey that collects data on drug use from an international sample of general population 
users. Information about health service engagement collected from general population AAS 
users is rare and access to the GDS data brings a unique aspect to this study. Most other 
surveys that have sought to explore behaviours, including the uptake of health services, have 
directly targeted steroid users in the gym environment (Davies et al., 2011; Lindqvist et al., 
2013; Pope et al., 2004) through needle and syringe programmes (Coomber et al., 2015; 
Iversen et al., 2016; Kimergård & McVeigh, 2014a; b) via specialist online forums (Chandler 
& McVeigh, 2013; Cohen et al., 2007; Parkinson & Evans, 2005) or through high schools 
(Buckley et al., 1988; Dunn & White, 2011; Johnstone et al., 2015; Pallesen et al., 2006; 
Tanner et al., 1995). Further, few of these studies have explored treatments received and none 
have examined the association between different types of medical interventions and service 
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satisfaction from the AAS users’ perspective. As AAS and PIEDs use amongst non-athletes 
increases, an important public health concern is to understand experiences of adverse health 
effects and related health seeking behaviours amongst general population AAS users. While 
the majority of surveys on AAS use collect only limited information about lifetime, past year 
and past month use with no information on experience of adverse effects and/or experience of 
health service engagement, the GDS 2015 survey tool measures a combination of patterns of 
AAS and PIEDs use and experience of adverse health issues and health seeking behaviours.  
Thus the current study was able to investigate aspects of AAS use not well understood from 
previous research in a general population sample. Important limitations must also be 
considered. Despite the very large sample size of the GDS, respondents are self-nominating 
and the sample is opportunistic. Further, the sample reporting recent steroid use is relatively 
small and virtually all report using recreational drugs in addition to AAS. Consequently, the 
sample used in the current study should not be considered representative of AAS using 
population. Relatively small numbers also preclude greater exploration of use by country of 
residence and therefore cannot account for variation in legislation and health service 
provision across different settings. Questions were limited to asking respondents about 
whether or not they had visited a family doctor but did not capture other forms of health 
service engagement such as visiting an emergency room or accessing injecting services and 
therefore our findings cannot be applied to health seeking behaviours more broadly.  
Despite these limitations, the current study provides some important insights into health 
service engagement among a general population sample of AAS users. The results suggest 
that health service providers can better assist AAS users by testing for specific side effects of 
AAS use. As a common reason for not engaging with services was stigma it is important that 
health service providers find subtle nuanced ways in which to demonstrate non-judgemental 
attitudes towards AAS use. This may be achieved by encouraging broader conversations 
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about mood, lifestyle and wellbeing. Providing access to information about injecting, steroid 
dosing and displaying information about steroid clinics in doctors’ surgeries may also help to 
demonstrate to AAS users that doctors are non-judgemental and willing to assist with 
monitoring health conditions associated with use.  
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Figure 1. MCA of  items measuring worry about adverse effects of AAS use  
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Table 1. Summary statistics  
Characteristics N % 
Age   mean=29.8 min =17 max.=72   
Sex    
      Male 253 (79.56) 
      Female 59 (18.55) 
Region of residence    
Europe 166 (52.20) 
North America 34 (10.69) 
South Americas 61 (19.18) 
Oceania 51 (16.04) 
Asia, Africa/Middle East 6 (1.89) 
Ethnicity   
White 263 (82.70) 
Non-white 55 (17.30) 
Poly-PIED use last 12 mths    
No AAS only 174 (54.72) 
Yes AAS plus at least 1 other  144 (45.28) 
Method of use    
Oral only 63 (28.13) 
Inject only 81 (36.16) 
Both oral and inject 80 (35.71) 
Worry about adverse effects    
Mood/Mental Health   
Anger/aggression   
Not at all worried 122 (61.31) 
Worried a little or a lot 77 (38.69) 
Depression/low mood   
Not at all worried 125 (63.45) 
Worried a little or a lot 72 (36.55) 
Rapid fluctuation in mood   
Not at all worried 118 (60.51) 
Worried a little or a lot 77 (39.49) 
Irrational excitability/elevation in mood   
Not at all worried 129 (65.48) 
Worried a little or a lot 68 (34.52) 
Restlessness/irritability   
Not at all worried 114 (57.58) 
Worried a little or a lot 84 (42.42) 
Loss of interest in other things;    
Not at all worried 141 (72.31) 
Worried a little or a lot 54 (27.69) 
Quality of relationship with others   
Not at all worried 130 (66.67) 
Worried a little or a lot 65 (33.33) 
Image   
Hair loss   
Not at all worried 119 (61.98) 
Worried a little or a lot 73 (38.02) 
Hair gain   
Not at all worried 135 (71.43) 
Worried a little or a lot 54 (28.57) 
Skin conditions   
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Not at all worried 84 (43.75) 
Worried a little or a lot 106 (56.25) 
Sexual function   
Sexual function   
Not at all worried 106 (53.81) 
Worried a little or a lot 91 (46.19) 
Sexual organs   
Effect on sexual organs   
Not at all worried 98 (50.78) 
Worried a little or a lot 95 (49.22) 
Reduction in breast size   
Not at all worried 164 (91.11) 
Worried a little or a lot 16 (8.89) 
Growth of breasts*   
Not at all worried 103 (54.50) 
Worried a little or a lot 86 (45.50) 
Increase in breast size   
Not at all worried 148 (82.68) 
Worried a little or a lot 31 (17.32) 
Organ Health   
Heart    
Not at all worried 87 (45.08) 
Worried a little or a lot 106 (54.92) 
Liver function   
Not at all worried 86 (44.79) 
Worried a little or a lot 106 (55.21) 
* We note this item is only applicable to male participants.
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Table 2. Logistic regression predicting doctors visit (n=186) 
 Full Model  Interaction Model 
 OR 95% CI  OR 95% CI 
User characteristics      
Age 1.03 (0.82,1.31)  1.03 (0.81,1.32) 
Age *Age 1.00 (0.99,1.00)  1.00 (0.99,1.00) 
Male 0.10** (0.02,0.40)  0.10** (0.02,0.47) 
      
Region of residence (ref: Europe)      
North America 6.26** (1.36,28.8)  5.11** (1.08,24.2) 
South Americas 1.58 (0.63,3.95)  1.51 (0.60,3.82) 
Oceania 1.49 (0.50,4.41)  1.42 (0.45,4.46) 
Asia, Africa/Middle East 0.34 (0.03,4.12)  0.31 (0.02,4.01) 
      
Poly-PIEDs use in last 12 mths (ref: AAS only) 0.76 (0.34,1.68)  0.80 (0.35,1.83) 
Method of administration (ref: oral only)      
Inject only 3.39 (1.09,10.6)  1.41 (0.18,10.9) 
Both oral and inject 3.14 (1.01,9.75)  5.36 (0.78,36.7) 
      
Worry of adverse effects      
Mood/mental health 0.65 (0.34,1.68)  0.60 (0.25,1.44) 
Image 1.29 (0.50,3.31)  1.14 (0.41,1.61) 
Sexual function 4.02** (1.56,10.3)  4.09** (1.56,10.7) 
Sexual organs 0.30* (0.11,0.86)  0.32* (0.11,0.91) 
Organ health 1.05 (0.43,2.60)  0.41 (0.11,1.51) 
      
Interaction: Method of admin.*Organ health      
Oral only*organ health    2.42 (0.26,22.6) 
Inject only*organ health    7.93* (1.23,51.3) 
      
Model information      
Constant  3.25 (0.03,351)  3.05 (0.03,348) 
Wald χ2 58.34  63.32 
LR test of improvement -89.22  -86.73 
Significant: *p<0.05, **p<0.01, ***p<0.001 
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Table 3.  Treatment received and service satisfaction 
 
N=68 % 
Helpfulness (z) Overall 
experience (z) 
Physical Examination     
Yes 54 79.41 1.42 1.00 
No 14 20.59   
Blood pressure     
Yes 50 26.47 -0.47 0.48 
No 18 73.53   
Assessment of mood     
Yes 23 33.82 2.71** 1.50 
No 45 66.18   
Blood tests to assess liver function     
Yes 55 80.88 0.05 0.19 
No 13 19.12   
Diabetes test     
Yes 28 41.18 2.10* 1.09 
No 40 58.82   
ECG     
Yes 26 38.24 1.37 0.98 
No 42 61.76   
Screening for hepatitis B/C, HIV     
Yes 28 41.18 1.68 2.62** 
No 40 58.82   
Discussion about safer injecting     
Yes 27 39.71 0.97 0.90 
No 41 60.29   
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Table 4. Reasons for not visiting a doctor 
 N=130 % 
Shame/stigma   
Yes 29 22.31 
No 101 77.69 
Did not think the doctor would be able to/ knowledgeable 
enough to help 
  
Yes 31 23.85 
No 99 76.15 
Did not think the doctor would be willing to help   
Yes 18 13.85 
No 112 86.15 
Concerns were not significant enough   
Yes 70 53.85 
No 60 46.15 
Worry over the impact on health insurance   
Yes 3 2.31 
No 127 97.69 
 
